每年出版 12 期
ISSN 打印: 1521-9437
ISSN 在线: 1940-4344
IF:
1.2
5-Year IF:
1.4
Immediacy Index:
0.3
Eigenfactor:
0.00066
JCI:
0.34
SJR:
0.274
SNIP:
0.41
CiteScore™::
2.8
H-Index:
37
Indexed in
Meal Ingestion of Ceraceomyces tessulatus Strain BDM-X (Agaricomycetes) Protects against Nonalcoholic Steatohepatitis in Mice
Get access
摘要
Nonalcoholic steatohepatitis (NASH) is becoming the most common cause of hepatocellular carcinoma (HCC) in developed countries. Oxidative stress plays a major role in the pathogenesis of NASH due to steatosis; hence, novel therapeutic approaches might include natural antioxidants. Ceraceomyces tessulatus strain Basidiomycetes-X (BDM-X), a novel edible mushroom, possesses potent antioxidant activity. This study aimed to investigate the hepato-protective effect of C. tessulatus BDM-X in a novel NASH-HCC mouse model. To prepare this animal model, 2-day-old C57BL/6J male pups were exposed to low-dose streptozotocin (STZ); at 4 weeks of age, they were randomly divided into two groups. The NASH group (NASH) received a high-fat diet (HFD32) up to 14 weeks of age; the C. tessulatus BDM-X group (BDM-X) received HFD32 up to age 10 weeks, followed by HFD32 + 20% BDM-X (percent weight per weight in the diet) up to age 14 weeks. Mice not treated with STZ and fed a normal diet served as a control group. We found that C. tessulatus BDM-X improved serum aminotransferase levels as well as histopathological features such as steatosis, inflammatory foci, and pericellular fibrosis in NASH mice. Hepatic protein expression of sterol regulatory element binding protein isoform SREBP-1 and peroxisome proliferator-activated receptor PPARα was significantly increased in NASH mice. C. tessulatus BDM-X treatment normalized the expression of both proteins. Our data suggest that C. tessulatus BDM-X may protect the liver against lipogenesis in NASH-HCC mice.
-
Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-38.
-
Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. J Hepatol. 2013;58:1218-29.
-
Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H, Yoneyama H. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepa-tocellular carcinoma. Med Mol Morphol. 2013;46(3):1-8.
-
Farrell GC, Rooyen D van, Gan L, Chitturi S. NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. Gut Liver. 2012;6:149-71.
-
Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203-12.
-
Borchers AT, Krishnamurthy A, Keen CL, Meyers FJ, Geshwin ME. The immunobiology of mushrooms. Exp Biol Med. 2008;233:259-76.
-
Luk S-U, Lee TK-W, Liu J, Lee DT, Chiu Y-T, Ma S, Ng IO-L, Wong Y-C, Chan FL, Ling M-T. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One. 2011;6(5):e19804.
-
Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, Shrode GE, Belury M, Adams LS, Williams D. Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res. 2006;66(24):12026-34.
-
Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, Nagamori N, Yanagita T. Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice. J Nutr Biochem. 2010;21(5):418-23.
-
Wang JC, Hu SH, Wang JT, Chen KS, Chia YC. Hypoglycemic effect of extract of Hericium erinaceus. J Sci Food Agric. 2005;85:641-6.
-
Huang T, Liu Y, Li H, Zhang Y, Kong D, Cui G. P-Glucan ameliorates nonalcoholic steatohepatitis induced by methionine and choline-deficient diet in mice. J Food Biochem. 2020;26:e13408.
-
Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, Peng RY. Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL/6 mice model via AMPK/Sirt1/SREBP-1c/PPARy pathway. Int J Mol Sci. 2020;21(1):360.
-
Nakashima A, Sugimoto R, Suzuki K, Shirakata Y, Hashiguchi T, Yoshida C, Nakano Y. Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis. Food Sci Nutr. 2018;8;7(1):139-47.
-
Watanabe T, Nakajima Y, Konishi T. In vitro and in vivo anti-oxidant activity of hot water extract of Basidiomycetes-X, newly identified edible fungus. Biol Pharm Bull. 2008;31(1):111-7.
-
Sakamoto T, Nishida A, Wada N, Nakamura Y, Sato S, Konishi T, Matsugo S. Identification of a novel pyrrole alkaloid from the edible mushroom Basidiomycetes-X (Echigoshirayukidake). Molecules. 2020;25(21):4879.
-
Matsuzawa T. Studies on antioxidant effects of culinary-medicinal Bunashimeji mushroom Hypsizygus marmoreus (Peck) Bigel. (Agaricomycetidae). Int J Med Mushrooms. 2006;8(3):245-50.
-
Ikekawa T. Beneficial effects of edible and medicinal mushrooms on health care. Int J Med Mushrooms. 2001;3(4):2.
-
Kikuo M, Tetsuo W, Susumu Y, Kikuo N. Clinical trials of Basidiomycetes-X on the patients with atopic dermatitis. Med Biol. 2007;151(9):306-11.
-
Fujikawa T, Shiraha H, Yamamoto K. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med Okayama. 2009;63(6):299-304.
-
Nakamura A, Zhu Q, Yokoyama Y, Kitamura N, Uchida S, Kumadaki K, Tsubota K, Watanabe M. Agaricus brasiliensis KA21 may prevent diet-induced NASH through its antioxidant, anti-inflammatory, and anti-fibrotic activities in the liver. Foods. 2019;8(11):546.
-
Fontes A, Alemany-Pages M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant versus pro-apoptotic effects of mushroom-enriched diets on mitochondria in liver disease. Int J Mol Sci. 2019;20(16):3987.
-
Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARa action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720-33.
-
Moslehi A, Hamidi-Zad Z. Role of SREBPs in liver diseases: A mini-review. J Clin Transl Hepatol. 2018;6(3):332-8.
-
Watanabe K, Afrin R, Sreedhar R, Karuppagounder V, Harima M, Alexander X, Velayutham R, Arumugam S. Pharmacological investigation of Ceraceomyces tessulatus (Agaricomycetes) in mice with nonalcoholic steatohepatitis. Int J Med Mushrooms. 2020;22(7):683-92.
-
Mochida K, Kuribayashi T, Saito K, Sugawara M. Production of sake lees powder and its effect on sterol metabolism of rat. Nippon Shokuhin Kagaku Kogaku Kaishi. 2000;47(2):78-84.
-
Manabe Y, Shobayashi M, Kurosu T, Sakata S, Fushiki T, Iefuji H. Increase in spontaneous locomotive activity in rats fed diets containing sake lees or sake yeast. Food Sci Technol Res. 2004;10(3):300-2.
-
Afrin R, Arumugam S, Rahman A, Wahed MII, Karuppagounder V, Harima M, Suzuki H, Miyashita S, Suzuki K, Yoneyama H, Ueno K, Watanabe K. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-KB translocation. Int Immunopharmacol. 2017;44:174-82.
-
Afrin R, Arumugam S, Soetikno V, Thandavarayan RA, Pitchaimani V, Karuppagounder V, Sreedhar R, Harima M, Suzuki H, Miyashita S, Nomoto M, Suzuki K, Watanabe K. Curcumin ameliorates streptozotocin-induced liver damage through modulation of endoplasmic reticulum stress-mediated apoptosis in diabetic rats. Free Radical Res. 2015;49(3):279-89.
-
Lillie RD. Further experiments with the Masson trichrome modification of Mallory's connective tissue stain. Stain Technol. 2009;15(1):17-22.
-
Pasumarthy L, Srour J. Nonalcoholic steatohepatitis: A review of the literature and updates in management. South Med J. 2010;103(6):547-50.
-
Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression. Hepatology. 2006;43(3):506-14.
-
Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, Derudas B, Lefebvre P, Taskinen M-R, Hul WV, Mertens I, Hubens G, Marck EV, Michielsen P, Gaal LV, Steals B. PPARa gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015;63(1):164-73.
-
Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-31.
-
Kozuka C, Kaname T, Shimizu-Okabe C, Takayama C, Tsutsui M, Matsushita M, Abe K, Masuzaki H. Impact of brown rice-specific y-oryzanol on epigenetic modulation of dopamine D2 receptors in brain striatum in high-fat-diet induced obesity in mice. Diabetologia. 2017;60(8):1502-11.
-
Jideonwo V, Hou Y, Ahn M, Surendran S, Morral N. Impact of silencing hepatic SREBP-1 on insulin signaling. PLoS One. 2018;13(5):e0196704.
-
Sato S, Sakurai M, Konishi T, Nishikawa K, Tsuno Y. Anti-obesity effect of Echigoshirayukidake (Basidiomycetes-X) in rats. Glycative Stress Res. 2019;6(4):198-211.
-
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253-61.
-
Matsugo Seiichi, Sakamoto Toshio, Wakame Koji, Nakamura Yutaka, Watanabe Kenichi, Konishi Tetsuya, Mushrooms as a Resource for Mibyou-Care Functional Food; The Role of Basidiomycetes-X (Shirayukidake) and Its Major Components, Nutraceuticals, 2, 3, 2022. Crossref